Organic Active Ingredients TRIZ Cases

Modified oligonucleotides suppress harmful RAN translation products while restoring FMR1 RNA and FMRP levels to treat fragile X-spectrum disorders.

Cholesterol 24-hydroxylase vector modulates brain metabolism to address neuronal dysfunction in polyglutamine repeat spinocerebellar ataxias.

Low-dose ketamine infusion alters brain oscillatory activity, reducing levodopa-induced dyskinesia while maintaining motor function.

A combination of herring oil and cold-pressed virgin olive oil reduces inflammatory responses.

Targeting CD33 lowers insoluble Aβ-42 levels and plaque burden, addressing incomplete understanding of late-onset Alzheimer's disease mechanisms.

Combining arginine with alpha-lipoic acid improves erectile function while minimizing severe side effects associated with conventional PDE5 inhibitors.

Java pepper extract addresses extraction complexity by optimizing solvent parameters to isolate bioactive compounds for vascular protection.

A copolymer composition promotes fibroblast proliferation and differentiation to accelerate tissue regeneration.

Substituted tetrahydro-benzodiazepinones bind BIR domains of inhibitor of apoptosis proteins.

Wet granulation with sodium stearyl fumarate resolves stability and manufacturing complexity contradictions in empagliflozin formulations.

N-Benzoyl-serine derivatives suppress melanocyte activation and tyrosinase activity, addressing the limited selectivity of conventional whitening agents.

Adhesive copolymer with permeation enhancers delivers fentanyl through skin, reducing device size and drug content.

Polymersomes sequester ammonia through a transmembrane pH gradient, avoiding invasive dialysis and adverse reactions.

Deoxynucleotides in the passenger strand stabilize siRNA molecules while ribonucleotides in the antisense seed region maintain gene silencing activity.

Replacing SpCas9 with a Cas12i polypeptide reduces off-target effects while enabling larger deletions for primary hyperoxaluria treatment.

Novel nucleoside analogues inhibit HBV DNA synthesis by targeting nucleocapsid assembly, reducing viral loads while minimizing drug resistance development.

Merges a sulfonamide compound with adjunct agents to enhance intraocular pressure lowering effects beyond single-drug limits.

Formula I compounds target Class IIa HDACs to resolve the contradiction between broad inhibition and selective disease treatment.

A carboxylic acid oral care composition selectively promotes beneficial bacteria growth and biofilm formation.

Antisense oligonucleotides inhibit active brain lesion conversion to reduce axonal loss and slow disability progression in multiple sclerosis.

Lipid nanoemulsions solubilize hydrophobic bioactive compounds, improving gastrointestinal absorption without synthetic excipients.

A 2-nitroimidazole derivative inhibits mitochondrial function in cancer stem cells to induce ferroptosis.

A pregnenolone derivative featuring a 3-benzyloxy substitution pattern that selectively inhibits the CB1 receptor.

Hydrophobic coating on sevelamer tablets prevents oral cavity swelling and masks bitter taste while maintaining phosphate binding capacity.

BET inhibitors overcome low response rates in BAP1 deficient cancers by targeting upstream gene expression rather than downstream signaling pathways.

A tissue-engineered nerve graft embeds polymeric nanomicrospheres carrying Let-7 family inhibitors or miR-21 mimics to promote axonal regeneration.

3-substituted 1,2,4-oxadiazole compounds modulate VISTA activity and the PD-1 signaling pathway to enhance immune responses.

A biodegradable polymeric composition shields the bowel during abdominal surgery using glycerolate and dihydroxyacetone materials.

PPARγ agonists activate the Nrf2 pathway to protect podocytes from crescent formation and glomerular injury.

Amorphous cannabinoid micelles improve gastric delivery by resolving poor aqueous solubility and bitter taste barriers.

Astaxanthin tetraterpenes inhibit PD-L1, sensitizing cancer cells to radiation and chemotherapy while reducing toxicity.

Bupropion metabolites inhibit CYP2D6 enzymes to extend dextromethorphan metabolic lifetime, resolving rapid clearance bottlenecks in extensive metabolizers.

Selective BRAF inhibition activates ERK signaling to induce senescence and sensitize tumors to checkpoint blockade.

Saccharide-based oral solid dosage forms eliminate reconstitution instability and reduce inter-individual variability in bendamustine absorption.

Metaxalone oral dosage inhibits MAO-A enzymes, restoring IL-13 levels and upregulating PGC-1α to promote white matter growth in neuroinflammatory conditions.

A nonselective metabotropic glutamate receptor activator treats anorexia nervosa and binge eating disorder symptoms.

Enzymatic hydrolysis and staged heating stabilize peptides against intestinal inactivation while lowering blood glucose.

Compounds block DUSP6-mediated negative regulation of ERK, overcoming resistance in BRAF and RAS mutated tumors.

A novel HPK1 inhibitor compound regulates kinase activity with high potency.

Piroxicam reduces CMV viral titer by 4.83 log10 levels, overcoming the limited efficacy of conventional antiviral drugs.

A beta-glucan composition from Aureobasidium pullulans modulates gut microbiota and balances amino acid levels.

Intermittent radiation activates photosensitizers in guiding channels, neutralizing albumin interference and destroying Gram-negative bacteria.

A flumazenil transdermal patch delivers sustained medication via controlled absorption, replacing invasive intravenous infusions to improve patient compliance.

Supercritical fluid processing creates lapatinib particles with controlled size and high surface area to boost dissolution rates.

Artificial exosomes overcome low yield and unclear mechanisms of natural exosomes by using segmented components like rab7 and desmoplakin.

Lauryl gallate induces platelet aggregation to arrest bleeding at wound sites.

Multi-target kinase inhibitors address inadequate fibrosis and cancer therapies by blocking CDK8, CDK19, HIPK2, and CK2a.

Ethylene-bridged oligooxopiperazines replace unstable peptide bonds to resolve conformational instability and enhance binding reliability.

A pyrimidine-4-carboxamide compound reduces liver lipid content and treats inflammation in animal models.